There is under-utilization of CRT devices in heart failure patients in the Northern Region of New Zealand, with observational data showing no difference in all-cause mortality between CRT-D and CRT-P recipients.
BACKGROUND: Cardiac resynchronization therapy (CRT) has been shown to improve morbidity and mortality for heart failure (HF) patients. Little is known about the trends in CRT use and outcomes of these patients in New Zealand. METHOD: Mortality, hospitalization events and complications in HF patients in the Northern Region of New Zealand implanted with CRT devices from Jan-2007 to June-2015 were reviewed. HF was the cause of death in 73.9% of the patients. There was no difference in all-cause mortality between patients with CRT-D and CRT-P. CONCLUSIONS: Despite the proven benefits of CRT in selected HF patients, there continued to be under-utilization of these devices in HF patients in the Northern Region. Reasons for under-utilization of these devices need further exploration. These data should be useful for benchmarking individual patient management and national practice against wider experience in the country.
No takes yet. Share an insight, caveat, or question.
Looi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: